EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieÄquivalenzstudieOpen Access

Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505)

Matthew M Poppe iD, Jennifer J Le-Rademacher iD, Bruce G Haffty iD, Eric K Hansen iD, Jayant P Agarwal, Jamie L Wagner iD, Iwa Kong iD, Jane M Armer, Doug W Arthur, Timothy J Whelan iD, Odum Kour, Minji K Lee iD und 9 weitere

Journal of Clinical Oncology · 10.11.2026 · 44 (32) · 3128-3138

DOI: 10.1200/jco-26-00474 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.11.2026. Verfasst von Matthew M Poppe und 20 weiteren Autor:innen. Beteiligte Einrichtung: Huntsman Cancer Institute, University of Utah, Salt Lake City, UT. Hauptthemen laut MEDLINE: Mammaplasty, Radiation Dose Hypofractionation, Mastectomy, Breast Neoplasms. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Patients with breast cancer requiring postmastectomy radiation therapy (PMRT) often desire breast reconstruction. Reconstructions can be adversely affected by PMRT, and fear of reconstruction complications has discouraged adoption of short-course radiation therapy used after lumpectomy. To fill the evidence gap, we conducted a noninferiority trial of hypofractionated versus conventional PMRT in patients undergoing breast reconstruction. The primary outcome was reconstruction complication rate, a composite of wound healing, readmission, capsular contracture, unplanned reoperation, and reconstruction failure. METHODS Women with unilateral invasive breast cancer with planned immediate or delayed reconstruction and PMRT were randomly assigned (1:1) to 50 Gy (25 fractions/5 weeks) or 42.56 Gy (16 fractions/3 weeks). This study was designed with a noninferiority margin of 10%, assuming a 2-year reconstruction complication rate of 25% with conventional PMRT. Randomization was stratified by immediate versus delayed and autologous versus implant-only reconstruction. RESULTS Between 2018 and 2021, 898 patients enrolled with a median follow-up of 3.9 years; 825 patients were evaluable for the primary end point. The 24-month reconstruction complication rates were 12.3% (52/422) with hypofractionated PMRT and 10.2% (41/403) with conventional PMRT, corresponding to an estimated difference of -2.1% (95% CI, -6.5 to 2.2). The complication rate was higher (regardless of arm) with implant-only versus autologous reconstruction (odds ratio = 1.65). There was no statistically significant difference in 36-month locoregional recurrence rates: 1.5% (95% CI, 0.7 to 3.2) with hypofractionated and 2.2% (95% CI, 1.1 to 4.3) with conventional PMRT. Acute and late toxicity rates were not statistically different. CONCLUSION A 16-fraction course of hypofractionated PMRT is safe and noninferior to conventional PMRT in women undergoing breast reconstruction after mastectomy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MammaplastyRadiation Dose HypofractionationMastectomyBreast NeoplasmsHumansFemaleMiddle AgedRadiotherapy, AdjuvantAgedAdult

Autor:innen und Institutionen

  • Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
  • Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN.
  • Rutgers Cancer Institute, New Brunswick, NJ.
  • The Oregon Clinic, Portland, OR.
  • University of Kansas, Kansas City, KS.
  • BC Cancer-Vancouver Centre, Vancouver, BC, Canada.

ORCID-Profile: Matthew M Poppe, Jennifer J Le-Rademacher, Bruce G Haffty, Eric K Hansen, Jamie L Wagner, Iwa Kong, Timothy J Whelan, Minji K Lee, Kathryn J Ruddy, Ann H Partridge, Lisa A Carey, Maryam Lustberg, Selina L Chow, Shane R Stecklein, David K Gaffney, Atif J Khan

Förderung

  • NCI NIH HHS

Zitieren

APA

Poppe, M. M., Le-Rademacher, J. J., Haffty, B. G., Hansen, E. K., Agarwal, J. P., Wagner, J. L., Kong, I., Armer, J. M., Arthur, D. W., Whelan, T. J., Kour, O., Lee, M. K., Ruddy, K. J., Partridge, A. H., Carey, L. A., Lustberg, M., Bernstein, M. B., Chow, S. L., Stecklein, S. R., …, & Khan, A. J. (2026). Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505). Journal of Clinical Oncology, 44(32), 3128-3138. https://doi.org/10.1200/jco-26-00474

Vancouver

Poppe MM, Le-Rademacher JJ, Haffty BG, Hansen EK, Agarwal JP, Wagner JL, et al. Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505). Journal of Clinical Oncology. 2026;44(32):3128-3138. doi:10.1200/jco-26-00474

BibTeX
@article{Poppe2026,
  author = {Poppe, Matthew M and Le-Rademacher, Jennifer J and Haffty, Bruce G and Hansen, Eric K and Agarwal, Jayant P and Wagner, Jamie L and Kong, Iwa and Armer, Jane M and Arthur, Doug W and Whelan, Timothy J and Kour, Odum and Lee, Minji K and Ruddy, Kathryn J and Partridge, Ann H and Carey, Lisa A and Lustberg, Maryam and Bernstein, Michael B and Chow, Selina L and Stecklein, Shane R and Gaffney, David K and Khan, Atif J},
  title = {Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505)},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {32},
  pages = {3128--3138},
  doi = {10.1200/jco-26-00474}
}
Kostenlos starten →